Cardinal Health recasts segment results under new structure for FY2022-H1 FY2024

CARDINAL HEALTH INC

New segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution; three smaller ops reported as Other.
Recast unaudited quarterly data for FY2022, FY2023, and H1 FY2024; no change to consolidated revenue or net income.
Pharm & Spec Solutions segment profit grew 13% in FY2023 to $1,862M; H1 FY2024 profit $961M.
Global Medical Products & Distribution segment losses: FY2022 loss $49M, FY2023 loss $162M, H1 FY2024 loss $2M.
Total segment revenue grew 13% in FY2023 to $205.1B; H1 FY2024 up 11% to $112.2B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.